Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
about
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.Pharmacogenomics and the treatment of acute myeloid leukemia.Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients.Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
P2860
Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@en
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@nl
type
label
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@en
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@nl
prefLabel
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@en
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@nl
P2093
P2860
P1476
Single nucleotide polymorphism ...... high-dose cytarabine therapy.
@en
P2093
Akifumi Ichiki
Hidetsugu Kawai
Hiroshi Kawada
Ken Ohmachi
Kiyoshi Ando
Makoto Onizuka
Masako Toyosaki
Minoru Kojima
P2860
P2888
P304
P356
10.1007/S12185-015-1766-4
P577
2015-03-04T00:00:00Z